Knowledge Exchange by ISID

Maximum: 1 CME cr.,
1 AutoAttendance cr.
Sign in to view your progression
Program Overview Progr...
Learning Objectives Learn...
Target Audience Targe...
References Refer...
Disclosure/Disclaimer Discl...

Activity Title: Dengue Vaccines: Directions for the Future
Release Date: December 8, 2022
Estimated Time to Complete Activity: 70 minutes

Statement of Need:
According to the WHO, the incidence of dengue has increased considerably in recent decades. Dengue is now endemic in more than 100 countries in Africa, the Americas, the Eastern Mediterranean, Southeast Asia, and the Western Pacific. Asia bears about 70% of the global burden of dengue. There is no specific treatment for dengue. So far, only one dengue vaccine CYD-TDV has been licensed for use. It is currently in use in about 20 countries globally. There are several candidate vaccines in different stages of development, some are currently in various stages of Clinical Trials. Several challenges have been faced in the development of vaccines, some of which include the nature of the virus itself, which has four serotypes, and the immune response to the vaccine.

Faculty: Anon Srikiatkhachorn (Thailand) and Cristina Barroso Hofer (Brazil)

Technical Requirements
This site and its activities are best viewed using the latest versions of the Chrome, Edge, Firefox and Safari browsers. For interactive content, a broadband connection is required. For CME/CE activities featuring audio you need a sound card and speakers.

Our activities may require JavaScript to be enabled on your computer. If you are having difficulty viewing pop-up windows, click here for instructions on enabling JavaScript.

Contact Information
If you have questions about this CME activity, please contact The International Society for Infectious Diseases at  info@isid.org.

For technical support issues, please contact Multilearning at support@multilearning.com

Upon completion of this module, participants should be able to:

  • Discuss the increase in dengue in recent decades
  • Know where dengue is endemic, and which area bears the global burden of the disease
  • Discuss how it is being treated, including the implementation of the CYD-TDV vaccine and other vaccines which are currently in various stages of Clinical Trials. 
  • Discuss the challenges that have been faced in the development of the vaccines,

The target audience for this module is physicians, nurses, public health officials, researchers, immunization officers, and other health professionals.

1.      Amorim, Jaime Henrique et al. Dengue vaccines: where are we now and where we are going? The Lancet Infectious Diseases 2022. Volume 22, Issue 6, 756 – 757
2.      Pinheiro-Michelsen JR, Souza SO, Santana IVR et al. Anti-dengue vaccines: from development to clinical trials. Front Immunol. 2020; 111252
3.      Rose, Anuradha et al. Bioethics of establishing a CHIM model for dengue vaccine development. International Journal of Infectious Diseases 2019. Volume 84, S74 - S79
4.       King, C.-C. Public health needs and challenges in influenza and dengue vaccines–Implications from epidemiological findings. International Journal of Infectious Diseases 2020 Volume 101, 324

 

Disclosure Policy
In accordance with the EACCME Standards for Commercial Support, the International Society for Infectious Diseases (ISID) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. ISID resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all our educational programs. Furthermore, ISID seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. ISID is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of commercial interest.

Activity Staff Disclosures:
The planners, reviewers, editors, staff, or other members at the International Society for Infectious Diseases who control content have no relevant financial relationships to disclose. 
ISID Knowledge Exchange and E-Learning Platform Organizing Committee members are listed here, along with Committee members’ disclosure forms. 

Faculty Disclosures:

Anon Srikiatkhachorn has no actual or potential conflict of interest in relation to this program
Cristina Barroso Hofer has no actual or potential conflict of interest in relation to this program

Disclosure of Unlabeled Use

The International Society for Infectious Diseases requires CME faculty (speakers) to disclose when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration-approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. ISID does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Disclaimer

The International Society for Infectious Diseases presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The International Society for Infectious Diseases, and the former commercial supporter assume no liability for the information herein.
Copyright Information
Copyright © 2022 by the International Society for Infectious Diseases. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:
•  The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
•  Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein), without the International Society for Infectious Diseases' prior written permission.
Privacy Policy
The International Society for Infectious Diseases protects the privacy of personal and other information regarding participants and educational collaborators. The International Society for Infectious Diseases will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the EACCME.
The International Society for Infectious Diseases maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.
Additional information regarding the International Society for Infectious Diseases Privacy Policy and ISID’s Knowledge Exchange and E-Learning Platform Privacy Policy can be viewed at https://isid.org/privacy-policy/ and https://exchange.isid.org/isid/legal/terms-and-conditions.

ACCREDITED ACTIVITY
Dengue Vaccines: Directions for the Future

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies